Emerging data suggest Retatru tide , a dual activator targeting both GLP-1 and GIP , appears to offer a notable step forward for weight management . Preliminary patient investigations have shown considerable decreases in visceral tissue, potentially surpassing existing weight-loss medications . However , additional study is needed to fully understa